BioNTech SE (FRA:22UA)
76.20
-0.10 (-0.13%)
Jun 3, 2026, 5:29 PM CET
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
€359,319
Profits / Employee
€160,395
Market Cap
19.27B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 177,783 |
| Fresenius Medical Care AG | 108,165 |
| Bayer Aktiengesellschaft | 87,757 |
| Siemens Healthineers AG | 73,800 |
| Merck KGaA | 59,077 |
| Fielmann Group AG | 18,928 |
| Sartorius Aktiengesellschaft | 14,242 |
| Ottobock SE & Co. KGaA | 10,365 |
BioNTech SE News
- 2 days ago - BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial - TheFly
- 4 days ago - Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - GlobeNewsWire
- 7 days ago - This Biotech's Cancer Portfolio Could End Its Rough Patch - Barrons
- 7 days ago - BioNTech upgraded to Buy from Neutral at UBS - TheFly
- 12 days ago - BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 13 days ago - Bernstein starts BioNTech at Market Perform, sees high registration risk - TheFly
- 13 days ago - BioNTech initiated with a Market Perform at Bernstein - TheFly
- 19 days ago - BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 - GlobeNewsWire